BigDNA  working on faster, cheaper and more effective ‘next generation’ vaccines, is to fund a collaborative research program with the University of Strathclyde's Institute of Pharmacy and Biomedical Science to help develop its patented phage vaccine technology.

“We look forward to collaborating with (right) Professor Stimson  and his team, to further understand the mechanism of action of our phage vaccines, and help optimise the technology” said (below left) Dr John March CEO of BigDNA.

"Outsourcing much of our basic research needs keeps our fixed costs low and allows us to access world-leading expertise which would take years for us to develop in house. This fits exactly with the latest ‘virtual company’ model for biotechnology development."

BigDNA will be working with Professor Stimson and Dr Dino Rotondo, senior lecturer at the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS) a research and training centre focussed on drug and vaccine design, discovery, development and use.

"This allows BigDNA to access world class research facilities while providing useful financial income to [Strathclyde] University [that] is at the forefront of participating in such partnerships .... a central plank of government plans for the Life Sciences sector," comments (right) Nigel Gaymond, CEO of the UK BioIndustry Association.